Influenza B virus conserved internal proteins (IBV internal proteins)

Influenza B virus conserved internal proteins represent a group of essential viral components, primarily the nucleoprotein (NP), matrix protein (M1), and the heterotrimeric polymerase complex consisting of PA, PB1, and PB2 subunits. Unlike the surface glycoproteins hemagglutinin and neuraminidase, which undergo rapid antigenic drift, these internal proteins remain highly stable across different Influenza B lineages, such as Victoria and Yamagata (Source: PubMed PMID 30135125). The nucleoprotein is responsible for encapsidating the viral RNA genome, while the polymerase complex drives viral replication and transcription through a unique "cap-snatching" mechanism (Source: Nature Communications 10, 1038). These proteins are critical targets for "universal" vaccine development, as they contain conserved epitopes capable of eliciting cross-reactive CD8+ T-cell responses that provide broad protection (Source: Vaccines 2021, 9(2), 126). Furthermore, the PA subunit of the polymerase is the specific target of the antiviral drug baloxavir marboxil, which inhibits the endonuclease activity required for viral mRNA synthesis (Source: FDA Label for Xofluza). Because this target name refers to a collection of distinct proteins rather than a single molecule, it is categorized as a target group or complex.

Other names

Influenza B internal antigensConserved IBV proteinsIBV NP, M1, and polymerase proteinsInfluenza B virus internal protein complex

Inhibition of viral RNA-dependent RNA polymerase activity, inhibition of cap-snatching endonuclease activity, and induction of cross-reactive T-cell mediated immunity against conserved epitopes.